Louisiana State Employees Retirement System Sells 100 Shares of Humana Inc. $HUM

Louisiana State Employees Retirement System trimmed its position in shares of Humana Inc. (NYSE:HUM) by 1.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,400 shares of the insurance provider’s stock after selling 100 shares during the period. Louisiana State Employees Retirement System’s holdings in Humana were worth $1,565,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of HUM. Vanguard Group Inc. raised its position in shares of Humana by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock valued at $3,697,222,000 after purchasing an additional 1,143,662 shares during the period. AQR Capital Management LLC raised its position in shares of Humana by 3,257.5% during the first quarter. AQR Capital Management LLC now owns 1,162,600 shares of the insurance provider’s stock valued at $307,624,000 after buying an additional 1,127,973 shares during the last quarter. Nuveen LLC bought a new stake in shares of Humana during the first quarter valued at approximately $171,220,000. Dodge & Cox raised its position in shares of Humana by 5.5% during the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock valued at $2,845,830,000 after buying an additional 557,175 shares during the last quarter. Finally, Pzena Investment Management LLC raised its position in shares of Humana by 6.1% during the first quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider’s stock valued at $1,013,133,000 after buying an additional 219,541 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Trading Down 3.6%

HUM stock opened at $280.24 on Monday. The firm has a fifty day moving average price of $279.45 and a 200 day moving average price of $258.04. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market cap of $33.71 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 1.64 and a beta of 0.42.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to analysts’ expectations of $31.85 billion. During the same period last year, the business posted $6.96 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Friday, September 26th. Humana’s payout ratio is presently 27.17%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Mizuho lifted their price objective on shares of Humana from $300.00 to $345.00 and gave the company an “outperform” rating in a research report on Thursday. Sanford C. Bernstein lifted their price objective on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Wells Fargo & Company lifted their price objective on shares of Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a research report on Tuesday, October 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Humana in a research report on Wednesday, October 8th. Finally, Bank of America lifted their price objective on shares of Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a research report on Friday. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $298.83.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.